Objectives: To evaluate brain metabolites in objective insomnia subtypes defined from polysomnography (PSG): insomnia with short sleep duration (I-SSD) and insomnia with normal sleep duration (I-NSD), relative to good sleeping controls (GSCs). H magnetic resonance spectroscopy (MRS) acquired in the left occipital cortex (LOCC), left prefrontal cortex, and anterior cingulate cortex was used to determine levels of creatine, aspartate, glutamate, and glutamine (referenced to water). Glutathione, glycerophosphocholine, lactate, myoinositol, and N-acetylaspartate measurements were also obtained. Sixteen GSCs were included for comparison. Multivariate analysis of variance was used to evaluate differences in creatine, aspartate, glutamate, and glutamine. Results: Aspartate and glutamine concentrations were reduced in the LOCC in I-SSD compared with I-NSD (both p < .05, d = .80-.99). Creatine displayed a nonsignificant mean reduction in I-SSD compared with I-NSD (p = .05, d = .58). Glutamine was reduced in I-SSD compared with controls (p < .05, d = .93). There were no differences in metabolites between all (I-SSD and I-NSD) insomnia patients and controls. In patients with insomnia, LOCC glutamine concentrations were found to be positively correlated with TST (r = .43, p < .05) and negatively correlated with wake-time after sleep onset (r = −.40, p < .05). Conclusions: Results indicate that I-SSD is associated with reduced brain metabolites in the LOCC compared with I-NSD and control concentrations of aspartate, glutamine, and creatine.
INTRODUCTION
Insomnia is associated with increased cognitive and physiological hyperarousal, inhibiting sleep, affecting daytime performance, and impairing health-related quality of life. [1] [2] [3] Two subtypes of insomnia have been proposed from total sleep time (TST) measured by polysomnography (PSG), and these groups differ on clinically meaningful outcomes. 4 Insomnia with short sleep duration (I-SSD) may be a more biologically severe subtype of insomnia associated with increased cognitive and physiological hyperarousal compared with insomnia with normal sleep duration (I-NSD). 4, 5 Previously, we used quantitative electroencephalography (EEG) to investigate cerebral hyperarousal at sleep onset and observed differences between subtypes of patients with insomnia. 6 As magnetic resonance spectroscopy (MRS) may infer cerebral hyperarousal through measurement of metabolite concentrations across the brain, 7 insomnia PSGdefined subtypes may differ in brain metabolites using MRS. 8 In the first use of MRS in insomnia, whole brain levels of γ-aminobutyric acid (GABA) were reduced in 16 insomnia patients (mean [SD] PSG-TST = 354 [59] minutes) compared with 16 good sleeping controls (GSCs). 9 Lower GABA levels were correlated with longer time awake during the night from PSG in insomnia. This is in line with the hyperarousal model of insomnia with GABA as the principal inhibitory neurotransmitter promoting sleep. 9, 10 Consistent with this finding, lower GABA levels (parieto-occipital cortex) were identified in 27 patients with post-traumatic stress disorder (PTSD) compared with 18 trauma-exposed controls without PTSD. Higher Insomnia Severity Index (ISI) scale scores were associated with lower GABA and higher glutamate (principal excitatory neurotransmitter) levels in these patients. 11 However, MRS GABA studies in insomnia have not been consistent. One study quantifying insomnia by symptoms identified reduced GABA in the occipital cortex and anterior cingulate cortex (ACC) in
Statement of Significance
This study measured brain metabolites in objectively defined subtypes of short and normal sleep duration insomnia. Insomnia patients with short objective sleep duration, defined from polysomnography, had reduced concentrations of glutamine, aspartate, and creatine compared with insomnia patients with normal sleep duration and good sleeping controls. Glutamine, a major substrate for γ-aminobutyric acid synthesis, was reduced in short sleep duration insomnia. In the overall insomnia group, glutamine concentrations were positively correlated with sleep duration and negatively correlated with wake-time after sleep onset. The overall group of insomnia patients did not have changes in brain metabolites compared with good sleeping controls.
20 insomnia patients compared with 20 controls. 12 In contrast, other work identified increased GABA in 16 insomnia patients (mean [SD] ambulatory PSG-TST = 302 [18] minutes) compared with 17 controls in the occipital cortex. 13 Higher GABA levels were associated with lower sleep duration in the insomnia group. Methodological differences between studies were suggested to explain these inconsistent findings. 10 Recent work evaluated diurnal effects (8:00-9:00 am and 10:00-11:00 pm MRS assessments) of GABA and glutamate/glutamine levels in 20 insomnia patients compared with 20 good sleepers in the ACC and dorsolateral prefrontal cortex. 8 GABA levels did not change across the day and were not different compared with controls. However, higher ACC levels of GABA were associated with increased PSG sleep duration on the second night, suggesting a trait marker of objective sleep disturbance. Importantly, the mean sleep length of the insomnia patients in this study was approximately 6 hours, suggesting the value of investigating patients with I-SSD for future MRS work. 8 Further brain metabolites may also have a role in insomnia pathophysiology. 9 Phosphorus MRS imaging found reduced phosphocreatine in insomnia (n = 16) compared with controls (n = 16), suggesting alteration in the adenosine triphosphate-to-adenosine diphosphate ratio consistent with hyperarousal.
14 Creatine is a marker of energy metabolism in both neurons and astrocytes, 15, 16 and concentrations have been shown to be reduced in patients with obstructive sleep apnea. [17] [18] [19] Glutamine, a major substrate for GABA synthesis, 20, 21 is increased with benzodiazepine administration 22 and decreased in depressive disorder (reflecting glutamatergic dysfunction). 23 Glutamine is synthesized from glutamate and both are correlated, with signal overlaps making them difficult to quantify separately in vivo. 24, 25 Both glutamate and glutamine appear important in insomnia as concentrations have been linked to sleep loss in patients with restless legs syndrome (n = 28), 26 and microinjection of glutamate in rats was associated with enhanced slow wave sleep. 27, 28 Previously, an indirect assessment of GABAergic and glutamatergic activation in insomnia patients (n = 18), using transcranial magnetic stimulation, found increased activation of glutamatergic but not GABAergic mechanisms compared with controls (n = 10). 29 Other work did not find differences in MRS glutamate or glutamine concentrations when compared with controls. However, these studies were not optimized to detect glutamate and glutamine concentrations. 9, 12, 13, 30 In this study, we used an asymmetric point-resolved spectroscopy (PRESS) sequence to more specifically measure both glutamate and glutamine concentrations. 24, 25, 31 Given the clinical differences between I-SSD and I-NSD, we aimed to examine brain concentrations of creatine, aspartate, glutamate, and glutamine in these two insomnia subtypes and controls.
METHODS

Participants
All participants were recruited from a volunteer database, advertisements in clinic, online, and in the local community and were initially screened over the telephone using a standardized assessment tool (based on Morin and Espie
32
). Eligible insomnia patients attended the sleep clinic and underwent a comprehensive sleep interview and medical examination by a Sleep Physician or Sleep Psychologist to determine the presence of insomnia disorder as specified by the Diagnostic and Statistical Manual of Mental Disorders -Fifth Edition. 33 This study was part of a larger insomnia phenotyping project (clinical trial registration [ANZCTR]: 12612000049875). 6 
Sleep
For insomnia patients only, one night of PSG was used to define sleep and objectively group patients into I-NSD and I-SSD subtypes through an empirical hierarchical cluster analysis. Ward's method (squared Euclidean distance) was used and identified two insomnia subgroups according to standardized (z-scores) clustering inputs of TST, sleep onset latency (SOL), and wake-time after sleep onset (WASO). 6 These variables (at least two must be used) were chosen based on previous insomnia phenotyping literature. 5, 34 Cluster analysis is useful as it provides a nonsubjective demarcation of patient cut-points from PSG. 35 To measure sleep, we applied a specific research montage (EEG: F3, Fz, F4, C3, Cz, C4, Pz, O1, Oz, O2, all signals used ground at FPz and common reference at CPz), electrooculographic (horizontal and vertical), electrocardiographic, and electromyographic (submental) recordings. Data were recorded on the Embla (Mortara, Broomfield, CO) system at 512 Hz and scored visually by one experienced sleep scorer to American Academy of Sleep Medicine criteria. 36 Each study was also independently checked for quality assurance by another independent expert scorer. Insomnia patients attended the laboratory between approximately 17:00 and 18:00, were set up between 20:00 and 21:00, and selected when to switch out the lights to initiate sleep. Participants refrained from alcoholic and caffeinated beverages on arrival to the sleep laboratory and lights were turned on at 06:00, which is standard in our laboratory.
Approximately 2 weeks after the overnight PSG, a subsample of insomnia patients underwent brain imaging if they met the following specific criteria: males and females aged between 21 and 55 years with insomnia specifically: difficulty initiating or maintaining sleep or waking up too early for at least three nights per week, for at least 3 months, with adequate opportunity and circumstances for sleep and a stable sleep/wake schedule, and a complaint of daytime impairment (eg, occupational, social, and academic settings). Insomnia patients were included with Apnea-Hypopnea Index (AHI) scores of less than 12 and periodic limb movement arousal index scores of less than 5 from PSG. In line with research diagnostic criteria for insomnia, 37 exclusion criteria included illicit substance or alcohol/caffeine dependence, severe or unstable psychiatric disorders (including those with major depressive disorder), a known sleep disorder other than insomnia, cognitive impairment, pregnancy or lactation, overnight shift workers and recent time-zone travel (within the last 2 months), and actively treated sleep disorder (eg, cognitive behavior therapy). Chronic hypnotic use was exclusionary (more than three times per week). Those with occasional hypnotic use (one to three times per week) at telephone screening were included but asked to refrain from hypnotic medication (under guidance from the Sleep Physician) throughout the study. The ISI 38 was used to define insomnia symptom severity.
GSCs were recruited to the insomnia patients by gender and age (within ±3 years). In line with research diagnostic criteria, 37 GSCs were defined by the absence of a sleep complaint, past diagnosis of a sleep or psychiatric or unstable medical disorder, and the endorsement of good sleep quality that was restorative and stable across the night (22:00-08:00 ± 2 hours), and they reported a normal SOL (<15 minutes), WASO (<15 minutes), TST (>6 hours), a high sleep efficiency (%SE > 85%), and low amount of night time awakenings (two or less) at telephone screening. 32 Any medication known to impact sleep was exclusionary. If deemed suitable from telephone screening, all participants recorded daily sleep diaries (similar to Morin and Espie
32
) and wore actigraph watches to verify stability of sleep timing (Actiwatch-2, Philips Respironics Mini-Mitter, Bend, OR) (see Figure 1 for an overview). All data were collected at the Woolcock Institute of Medical Research, University of Sydney and Neuroscience Research Australia, Australia. All scans were standardized to the afternoon-early evening. This study was reviewed and approved by the Royal Prince Alfred Hospital Ethics Review Committee, Sydney, Australia (Protocol No. X11-0392 and HREC/11/RPAH/620); clinical trial registration number: 12612000050853 (ANZCTR). All participants gave written informed consent.
Clinical and Demographic Outcomes
Demographic variables included age, sex, body mass index (BMI, kg/m 2 ), and duration of insomnia symptoms (years) and were assessed by a self-reported electronic questionnaire. Insomniarelated patient-reported questionnaires were also captured by electronic questionnaire including the ISI, 38 the 21-item version of the Depression Anxiety and Stress Scale (DASS), 39 Epworth Sleepiness Scale (ESS), 40 Flinders Fatigue Scale (FFS), 41 16-item version of the Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS), 42 and the Ford Insomnia Response to Stress Test (FIRST). 
Magnetic Resonance Spectroscopy
Proton 1 H-MRS was used as a measure of relative intracerebral concentrations of metabolites in vivo. To measure metabolites, we used an optimized approach for spectral acquisition which allows better discrimination of closely related resonances of glutamine, glutamate, creatine, and aspartate (with relatively small estimation errors). 31 An asymmetric PRESS sequence (a modification of Snyder and Wilman 25 , see Rae et al. 31 ) was used with an echo time (TE) of TE1 = 25 ms, TE2 = 85 ms, and a repetition time (TR) of 2 seconds. Alongside this, an additional short echo PRESS sequence was also acquired (TE = 32 ms). All spectra were acquired at 3T (Achieva TX, Philips, Best, The Netherlands) using a 32-channel head coil with concomitant water reference spectra. In line with previous findings, three regions of interest (ROI; 2 × 2 × 2 cm) were selected a priori. The left occipital cortex (LOCC) was selected as the primary site of interest as differences in GABA were previously detected here in insomnia. 9, 12, 13 Secondary exploratory locations of interest, including the middle ACC and left medial prefrontal cortex (LPFC), were assessed in line with previous insomnia literature. 8, 12, 30, [44] [45] [46] [47] [48] Acquired T1 images (TR = 2530 ms; TE = 3.65 ms; flip angle = 7°; slice thickness = 1 mm, 224 slices; field-of-view = 256 × 176 mm 2 ; matrix size = 256 × 256) were used to guide the placement of the ROI for MRS measurements (see Figure 2 , a).
All spectra were visually inspected for quality, including evidence of patient movement and the presence of artifacts, 49 and poor shimming based on line width assessment. Acceptable spectra were fitted by CDR blind to participant group with jMRUI (v. 4, build 162) using the QUEST algorithm, 50 with metabolite basis sets simulated for the appropriate sequence timings with NMR SCOPE, relying on published chemical shift and coupling constant information. 51 Creatine, aspartate, glutamate, and glutamine were acquired and assessed. Glycerophosphocholine, lactate, glutathione, myoinositol, and N-acetylaspartate were also fitted for spectra. All identified metabolites were referenced to water (see Figure 2, b) . 52 Spectroscopy ROIs were assessed for relative contributions of gray and white matter using a tool for partial volume estimation of Philips data. 53 After spectroscopy acquisition, we also obtained high angular resolution diffusion-weighted imaging acquired with diffusion weighting (B = 2400 s/mm 2 ) along 61 non-collinear directions for structural white matter assessment, and an echo planar imaging resting state time series. 
Brain Volumetric Assessment
Brain volumes were calculated after being segmented and parcellated using Freesurfer (v. 5.3.1). 54, 55 Whole brain volumes were calculated and normalized for brain size using SIENAX, 56 part of FMRIB's Software Library, 57 and used to calculate relative volumes for ROIs.
Statistical Analysis
Differences in demographic, clinical, sleep, and brain volumetric variables were assessed through univariate one-way analysis of variance or chi-squared tests between groups for insomnia subtypes (I-SSD and I-NSD) versus GSCs (Table 1) . For brain volumetric variables only, intracranial volume was instated as a covariate. Between subjects one-factor multivariate analysis of variance (MANOVA) was used to evaluate creatine, aspartate, glutamate, and glutamine concentrations. MANOVA is the best approach as it allows exploration of complex related data between groups for multi-dependent variables (eg, Huberty and Olejnik 58 and Meyers et al. 59 ). MANOVA was used for each of the three brain ROIs and for the comparison of insomnia subtypes (I-SSD and I-NSD) versus GSCs and insomnia versus GSCs. Follow-up pairwise comparisons using the least significant difference method assessed individual metabolites between groups. Effect size scores (d) were calculated for group comparisons. Exploratory correlations assessed the association between metabolites and objective sleep metrics (TST, SOL, and WASO). Alpha was set at less than .05. We measured potential confounders including, age, sex, time of scanning, handedness, female menstrual cycle, and occasional self-reported hypnotic use. 8 All data were analyzed (by CBM) using Statistical Package for the Social Sciences (SPSS) software (IBM v. 22.0.0; IBM Corp., Armonk, NY).
RESULTS
Participant Characteristics
Thirty-one patients with insomnia (n = 21 [68%] females; average age [SD] = 37.5 [9.9] ) and 16 GSCs (n = 11 [69%] females; average age [SD] = 37.3 [9.6]) participated in this study. Due to patient-control recruitment, the control group was very similar to the insomnia groups for mean age, sex distribution, and BMI (see Table 1 ). Seven-to-fourteen days of sleep diary data confirmed subjective sleep disturbance in insomnia subtypes with stable sleep timing from actigraphic recordings ( Table 2) . Good sleep quality was observed in GSCs with significant and healthy scores for the Pittsburgh Sleep Quality Index (PSQI) compared with insomnia patients (p < .001). As expected, patients with insomnia had higher ISI and DASS -depression, anxiety, and stress scale scores than GSCs (see Table 1 ). Although the DASS -depression and anxiety scores were higher compared with controls, they were still in the normal-tomild range, and the stress scores were clinically elevated. The ISI scores were in the moderate range of insomnia severity. The average duration of insomnia was 11.9 (range 1-20) years. PSG data are presented in Table 3 for the insomnia patients only. Insomnia patients were all grouped into either I-NSD or I-SSD subtypes through an empirical cluster analysis using TST, SOL, and WASO from PSG. 6 Creatine, Aspartate, Glutamate, and Glutamine For creatine, aspartate, glutamate, and glutamine, we report data from 30 patients with insomnia out of the 31 who consented into the study and 16 GSCs. The first patient was treated as a pilot and ROI placement was subsequently improved, so the spectra from this patient could not be included in the analysis. For the LOCC only, on checking the distribution of the dependent variables, a clear outlier (with low values) from the I-SSD group was detected across the four variables (creatine = 8.2; aspartate = 0; glutamate = 7.6; glutamine = 2.3 parts per million [ppm]). On inspection of this patient, this was attributed to movement during this acquisition. To be statistically conservative, the following data reported exclude this patient, however; a sensitivity analysis including this patient did not change the results.
Insomnia Subtype Analysis
Using data from the asymmetric PRESS acquisitions, the LOCC approached significance (Wilks' λ = .707, F(8, 78) = 1.85; p = .081; partial η 2 = .159) and follow-up individual variable comparisons were undertaken. Creatine displayed a nonsignificant mean reduction in I-SSD versus I-NSD only (p = .05, d = .58; see Figure 3 and Table 4 ). Aspartate and glutamine were reduced in I-SSD versus I-NSD (p < .05, d = .80-.99). Glutamine was reduced in I-SSD versus GSCs (p < .05, d = .93; see Table 4 ). For the secondary exploratory ROIs, there were no significant differences from MANOVA between insomnia subtypes (I-NSD vs. I-SSD) and GSCs at the LPFC (Wilks' λ = .872, F(8, 80) = 0.71; p = .682; partial η 2 = .066) or ACC (Wilks' λ = .863, F(8, 80) = 0.77; p = .633; partial η 2 = .071). Potential confounders including time of scanning, handedness, female menstrual cycle, and self-reported occasional hypnotic use in insomnia patients were not associated with either insomnia or brain metabolites. Age was associated with brain metabolites and a subsequent sensitivity analysis adjusting for age for the LOCC gave similar results to the unadjusted results presented here (Wilks' λ = .666, F(8, 76) = 2.14; p = .041; partial η 2 = .184), with creatine and glutamine both reduced in I-SSD compared to both I-NSD (p = .014 and p = .028, respectively) and GSCs (p = .013 and .046). Aspartate was no longer significantly reduced in I-SSD compared to I-NSD (p = .054).
There were no differences for any metabolites at any of the ROIs using the standard short PRESS sequence. Supplementary Figure  S1 displays the untested metabolites including N-acetylaspartate, glycerophosphocholine, lactate, and myoinositol acquired at the LOCC between groups. Glutathione was left out as this measure remains to be validated in asymmetric PRESS.
Insomnia versus GSCs
There were no significant differences between the overall insomnia sample and GSCs for creatine, aspartate, glutamate, and glutamine in the LOCC using the asymmetric PRESS Table 4 ). There were also no differences for any metabolites at any of the secondary ROIs using the standard PRESS sequence.
Exploratory Associations With Objective Sleep Parameters in Insomnia
In patients with insomnia, only glutamine concentrations were found to be significantly correlated with sleep parameters at the LOCC. TST was positively correlated (r = .43, p < .05) and WASO was negatively correlated (r = −.40, p < .05). SOL did not correlate with glutamine (p = .704) (see Supplementary Figure S2 ).
Voxel Volumetric Assessment
There were no between-group differences (insomnia vs. GSCs) for univariate analyses of variance for gray and white matter volumes in the LOCC, LPFC, or ACC (F(1, 42-43) = 0.00-3.24, p = .079-.991). The ACC only displayed a trend for significance in gray matter volume (p = .079). Similarly, no differences were found between insomnia subtypes (I-SSD, I-NSD) and GSCs (F(2, 41-42) = 0.01-1.64, p = .206-.822).
DISCUSSION
Clinical insomnia research has shown differences between patients with I-SSD and I-NSD. 4 Consistent with these findings, Mean and SD for aspartate, creatine, glutamate, and glutamine (parts per million). GSC, good sleeping controls (n = 16); I-NSD, insomnia with normal sleep duration (n = 18); INS, overall insomnia group including both I-NSD and I-SSD patients (n = 30); I-SSD, insomnia with short sleep duration (n = 12: apart from the left occipital cortex where n = 11).
our study shows reduced concentrations of brain metabolites in the LOCC in those with I-SSD compared with I-NSD and GSCs. These findings were most apparent for glutamine concentrations. In the overall insomnia sample, LOCC glutamine concentrations were positively correlated with TST and negatively correlated with WASO. We also found a reduction in aspartate and a nonsignificant reduction in creatine in the LOCC for those with I-SSD. The LOCC appears to be a key region differentiating GABA concentrations in insomnia and controls in previous studies, 12, 13 and now for further brain metabolite variables in I-SSD. Although we did not find differences in brain metabolites between GSCs and combined I-NSD and I-SSD patients, using MRS in different PSG-determined sleep duration insomnia subtypes may allow us to further understand the pathophysiology of insomnia. 4 Glutamine is important as it is a major substrate for the synthesis of GABA. 20, 21 GABA was reported to be reduced in insomnia 9, 12 but these studies did not detect differences in glutamine. 9, 12, 13, 30 Glutamine is difficult to measure with standard PRESS sequence timings. 24, 25, 31 In the present study, metabolite concentrations were measured using a relatively long echo asymmetric PRESS sequence. We did not detect metabolite differences using a short echo PRESS sequence. Glutamine measurement using short echo PRESS is suboptimal. 25 The longer asymmetric PRESS sequence was specifically designed to detect glutamine with improved accuracy 25, 31 Results are in line with previous work as they suggest glutamine concentrations may only be reduced in a specific I-SSD subtype. Our findings are potentially valuable as they link sleep duration to glutamine concentrations in insomnia. As benzodiazepines are known to increase concentration ratios of glutamine, glutamate, and GABA, 22 we speculate that phenotyping insomnia patients using MRS may help delineate the role of benzodiazepines for the treatment of I-SSD. 5 Previous insomnia MRS studies have shown mixed results, with both higher 13 and lower 12 LOCC concentrations of GABA using creatine as the reference metabolite. Short echo PRESS measures total creatine which is a composite of phosphocreatine and creatine. At longer TEs, such as with our asymmetric PRESS (TE = 110 ms), the creatine signal is more revealing of changes in the ratio of creatine to phosphocreatine due to the relative difference in T2 relaxation times. 60 Creatine concentration differences in insomnia subtypes may explain these inconsistent findings. Further measurement of these metabolites and GABA, independent of creatine in subtypes of insomnia, is required to verify the reliability of these initial findings. Other work also observed increased GABA levels associated with longer PSG-defined sleep duration, suggesting a possible trait marker of sleep length. 8 These findings were made in the ACC and the LOCC was not investigated. In our study, the LPFC, the middle ACC, and the LOCC were all explored and only between-group differences in the LOCC were identified. However, the LOCC was not associated with gray or white matter differences. This further supports the need to include the LOCC for assessment in relation to insomnia subtypes. Consistent with this study, reduced phosphocreatine levels have previously been identified in insomnia, suggesting alteration in the adenosine triphosphate-to-adenosine diphosphate ratio consistent with hyperarousal.
14 Whether or not these changes occur prior to the development of insomnia or reflect an adaptive response remains unanswered. There are a number of limitations associated with this study. Causality regarding sleep and brain metabolite concentrations is difficult to determine given the nature of the cross-sectional study design. We identified a relatively small number of patients with I-SSD, based on one night of PSG limiting the generalization of these findings; however, the overall sample size is comparative to previous samples of insomnia patients using MRS. A Type I statistical error is plausible with the use of multiple exploratory MANOVAs across the three locations of the brain for each of the two hypotheses. A lack of statistical power may have caused a Type II error and results require verification in larger groups of patients with I-SSD. We used multiple follow-up comparisons for each dependent variable without correction on a MANOVA with a nonsignificant trend (p = .081). We believe this is appropriate given the use of MANOVA as a nonspecific omnibus test with our a priori hypothesis and the findings of the LOCC in previous insomnia MRS studies. Insomnia patients were grouped using cluster analysis, a nonsubjective data-driven method of generating short and normal sleep duration phenotypes from PSG-derived measures of TST, SOL, and WASO. 6 We did not use a more traditional 6-hour cut-point in PSG sleep duration to define subtypes 5 and cluster classification error may account for findings. A sensitivity analysis using a 6-hour cut-point in TST to define subtypes, however, suggested similar results as reported here with significant reductions in I-SSD creatine and glutamine concentrations compared to both I-NSD and controls in the LOCC. Aspartate and glutamate were not significantly reduced. Scanning time limitations did not allow the quantification of GABA. Measurement of GABA may have enhanced the interpretation of study findings. Unlike previous MRS insomnia studies, we used water as the denominator to infer absolute metabolite concentrations and not creatine. 8, 9, 12, 13 Use of the water resonance reduces variability in 1 H-MRS measurements. 52 Previous studies using creatine as a reference assumed it to be stable which may not be the case from results presented here. Uncertainty in the measurement of aspartate may be a source of error and this metabolite should be interpreted with caution.
Insomnia patients were included with AHI less than 12, AHI was not different between cluster groups, did not correlate with metabolites, and when added to the model as a covariate, it did not change our findings. A further limitation was a lack of PSG evaluation in our control group and we are unable to rule out the presence of occult sleep disorders in this group. However, we believe this was mitigated as multiple assessments were undertaken including telephone screening, actigraphy, sleep diaries, and questionnaires. We did not have access to a group of participants who were sleep restricted but otherwise healthy and cannot clarify whether the results here are due to insomnia or short sleep duration. Confounders including female menstrual cycle may have affected results. Out of 21 females who reported a regular menstrual cycle, 14 were in the follicular phase and 6 in the luteal phase (it was not possible to code one response) at the time of scanning; yet brain metabolites were not associated with cycle phase or insomnia. We did not conduct toxicology to rule out medications that may have affected sleep or brain metabolites and relied upon self-report. Five insomnia patients
